{
  "docId": "019de072-b09f-7797-83e5-c925df87e1b3",
  "docSlug": "fb96dc8e32131cd826524e728a742819",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 36,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Clinical trial schema showing randomization of 685 patients into Durvalumab+GemCis or Placebo+GemCis arms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-b09f-7797-83e5-c925df87e1b3/12",
  "deckHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3",
  "deckJsonHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3.json",
  "deckAnchorHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Study flow from eligibility to randomization and treatment arms",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dca9c5f-1166-4d04-bac4-5d4bfda3d503",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.55,
        "y": 0.55
      },
      "kind": "list",
      "text": "Primary and secondary objectives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99ebfa0d-8b53-4d3c-9e57-a2984c2df6f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Stratification factors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7b1320d-c65d-4b7c-931a-5e4e3425741b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "Key eligibility criteria",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8c2598e-a11a-4380-ade7-8a3928fe8c42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.2,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "TOPAZ-1 is a double-blind, multicenter, global, Phase 3 study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac13caf8-9c8b-4e18-9342-b330c939b3ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "GemCis treatment: gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 Q3W administered for up to 8 cycles.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f5f5a6e-1be8-4aa0-964e-eb10ac88a390",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "TOPAZ-1 study design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5e4b6ce-65d4-4e0d-99db-7a2be8ad6acf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-schema",
      "slug": null,
      "matchId": "3c3ac2ff-be8c-4978-8f34-8da516de4857",
      "evidence": "Standardized visual representation of patient flow in a clinical study",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 6,
      "beatId": "4553c68f-c8a6-4cb5-9d28-9bc65dfd58fa",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 6-17 identify the problem, highlighting the unmet needs in BTC treatment.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}